A review of human diseases caused or exacerbated by aberrant complement activation

Neurobiology of Aging

Volumn 52, Issue , 2017, Pages 12-22

  McGeer, Patrick L ^a   Lee, Moonhee ^a   McGeer, Edith G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Complement; Complement receptors; Complement mediated diseases; Membrane attack complex

Indexed keywords

CD11B ANTIGEN; CD59 ANTIGEN; CLUSTERIN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C3D RECEPTOR; COMPLEMENT COMPONENT C4 BINDING PROTEIN; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5A; COMPLEMENT FACTOR H; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT RECEPTOR; COMPLEMENT RECEPTOR C3A; COMPLEMENT RECEPTOR C5A; DECAY ACCELERATING FACTOR; ECULIZUMAB; FIBRINOGEN; GLYCOPROTEIN P 15095; LYMPHOCYTE FUNCTION ASSOCIATED PROTEIN; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

AGE RELATED MACULAR DEGENERATION; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ATHEROSCLEROSIS; ATYPICAL HEMOLYTIC UREMIA SYNDROME; B CELL LYMPHOMA; BREAST CANCER; BURN; COMPLEMENT ACTIVATION; CROHN DISEASE; DERMATITIS HERPETIFORMIS; DISEASE COURSE; DISEASE EXACERBATION; EPILEPSY; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TRANSPLANTATION; MALARIA; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEUROBLASTOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOGENESIS; PEMPHIGUS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; SKIN ALLERGY; TRAUMATIC BRAIN INJURY; ULCERATIVE COLITIS; UVEITIS; CHRONIC DISEASE; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; DEGENERATIVE DISEASE; GENETICS; IMMUNOLOGY; MACULAR DEGENERATION; MOLECULARLY TARGETED THERAPY;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; HUMANS; MACULAR DEGENERATION; MOLECULAR TARGETED THERAPY; MULTIPLE SCLEROSIS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; RECEPTORS, COMPLEMENT;

EID: 85009291208     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2016.12.017     Document Type: Review

References (116)

1. Aeinehband, S., Lindblom, R.P., Al Nimer, F., Vijayaraghavan, S., Sandholm, K., Khademi, M., Olsson, T., Nilsson, B., Ekdahl, K.N., Darreh-Shori, T., Piehl, F., Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis. PLoS One, 10, 2015, e0122048.
2. Ahrenstedt, O., Knutson, L., Nilsson, B., Nilsson-Ekdahl, K., Odlind, B., Hallgren, R., Enhanced local production of complement components in the small intestines of patients with Crohn's disease. N. Engl. J. Med. 322 (1990), 1345–1349.
3. Anderson, D.H., Radeke, M.J., Gallo, N.B., Chapin, E.A., Johnson, P.T., Curletti, C.R., Hancox, L.S., Hu, J., Ebright, J.N., Malek, G., Hauser, M.A., Rickman, C.B., Bok, D., Hageman, G.S., Johnson, L.V., The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis revisited. Prog. Ret. Eye Res. 29 (2010), 95–112.
4. Argyriou, A.A., Makris, N., Neuromyelitis optica: a distinct demyelinating disease of the central nervous system. Acta Neurol. Scand. 118 (2008), 209–217.
5. Aronica, E., Boer, K., van Vliet, E.A., Redeker, S., Baayen, J.C., Spliet, W.G., van Rijen, P.C., Troost, D., da Silva, F.H., Wadman, W.J., Gorter, J.A., Complement activation in experimental and human temporal lobe epilepsy. Neurobiol. Dis. 26 (2007), 497–511.
6. Bahia El Idrissi, N., Bosch, S., Ramaglia, V., Aronica, E., Baas, F., Troost, D., Complement activation at the motor end-plates in amyotrophic lateral sclerosis. J. Neuroinflammation, 13, 2016, 72.
7. Barnum, S.R., Niemann, M.A., Kearney, J.F., Volanakis, J.E., Quantitation of complement Factor D in human serum by a solid-phase radioimmunoassay. J. Immunol. Methods 67 (1984), 307–309.
8. Bateman, R.J., Xiong, C., Benziger, T.L.S., Fagan, A.M., Goate, A., Fox, N.C., Marcus, D.S., Cairns, N.J., Xie, X., Blazey, T.M., Holtzman, D.M., Santacruz, A., Buckles, V., Oliver, A., Moulder, K., Aisen, P.S., Ghetti, B., Klunk, W.E., McDade, E., Martins, R.N., Masters, C.L., Mayeux, R., Ringman, J.M., Rossor, M.N., Schofield, P.R., Sperling, R.A., Salloway, S., Morris, J.C., Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. New Engl. J. Med. 367 (2012), 793–804.
9. Bellander, B.M., Singhrao, S.K., Ohlsson, M., Mattsson, P., Svensson, M., Complement activation in human brain after traumatic brain injury. J. Neurotrauma 18 (2001), 1295–1311.
10. Biryukov, S., Stoute, J.A., Complement activation in malaria: friend or foe?. Trends Mol. Med. 20 (2014), 293–301.
11. Brennan, F.H., Anderson, A.J., Taylor, S.M., Woodruff, T.M., Ruitenberg, M.J., Complement activation in the injured central nervous system: another dual-edged sword?. J. Neuroinflamation, 9, 2012, 137.
12. Bresin, E., Rurali, E., Caprioli, J., Sanchez-Corral, P., Fremeaux-Bacchi, V., Rodriguez de Cordoba, S., Pinto, S., Goodship, T.H., Alberti, M., Ribes, D., Valoti, E., Remuzzi, G., Noris, M., European Working Party on Complement Genetics in Renal Diseases. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical genotype. J. Am. Soc. Nephrol. 24 (2013), 475–486.
13. Brodeur, J.P., Ruddy, S., Schwartz, L.B., Moxley, G., Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis. Arthritis Rheum. 34 (1991), 1531–1537.
14. Compston, D.A., Morgan, B.P., Campbell, A.K., Wilkins, P., Cole, G., Thomas, N.D., Jasani, B., Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol. Appl. Neurobiol. 15 (1989), 307–316.
15. Dahl, M.V., Falk, R.J., Carpenter, R., Michael, A.F., Membrane attack complex of complement in dermatitis herpetiformis. Arch. Dermatol. 121 (1985), 70–72.
16. Dasari, P., Fries, A., Heber, S.D., Salama, A., Blau, I.W., Lingelbach, K., Bhakdi, S.C., Udomsangpetch, R., Torzewski, M., Reiss, K., Bhakdi, S., Malaria anemia: digestive vacuole of Plasmodium falciparum mediates complement deposition in bystander cells to provoke hemophagocytosis. Med. Microbiol. Immunol. 203 (2014), 383–393.
17. Depboylu, C., Schäfer, M.K., Arias-Carrión, O., Oertel, W.H., Weihe, E., Höglinger, G.U., Possible involvement of complement factor C1q in the clearance of extracellular neuromelanin from the substantia nigra in Parkinson disease. J. Neuropathol. Exp. Neurol. 70 (2011), 125–132.
18. Ehrnthaller, C., Ignatius, I., Gebhart, F., Huber-Lang, I., New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol. Med. 17 (2011), 317–329.
19. Eikelenboom, P., Hack, C.E., Rozemuller, J.M., Stam, F.C., Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 56 (1989), 259–262.
20. Eikelenboom, P., Stam, F.C., Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol. 57 (1982), 239–242.
21. Eikelenboom, P., Stam, F.C., An immunohistochemical study on cerebral vascular and senile plaque amyloid in Alzheimer's dementia. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 47 (1984), 17–25.
22. Fan, X., Yoshida, Y., Honda, S., Matsumoto, M., Sawada, Y., Hattori, M., Hisanaga, S., Hiwa, R., Nakamura, F., Tomomori, M., Miyagawa, S., Fujimaru, R., Yamada, H., Sawai, T., Ikeda, Y., Iwata, N., Uemura, O., Matsukuma, E., Aizawa, Y., Harada, H., Wada, H., Ishikawa, E., Ashida, A., Nangaku, M., Miyata, T., Fujimura, Y., Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome. Mol. Immunol. 54 (2013), 238–246.
23. Fernandez-Arias, C., Lopez, J.P., Hernandez-Perez, J.N., Bautista-Ojeda, M.D., Branch, O., Rodriguez, A., Malaria inhibits surface expression of complement receptor 1 in monocytes/macrophages, causing decreased immune complex internalization. J. Immunol. 190 (2013), 3363–3372.
24. Formeris, F., Ricklin, D., Wu, J., Tzekou, A., Wallace, R.S., Lambris, J.D., Gros, P., Structures of C3b in complex with Factors B and D give insight into complement convertase formation. Science 330 (2010), 1816–1820.
25. Fridkis-Harell, M., Storek, M., Mazsaroff, I., Risitano, A.M., Lundberg, A.S., Horvath, C.J., Holers, V.M., Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood 118 (2011), 4705–4713.
26. Gasque, P., Chan, P., Mauger, C., Schouft, M.T., Singhrao, S., Dierich, M.P., Morgan, B.P., Fontaine, M., Identification and characterization of complement C3 receptors on human astrocytes. J. Immunol. 156 (1996), 2247–2255.
27. Gold, B., Merriam, J.E., Zernant, J., Hancox, L.S., Taiber, A.J., Gehrs, K., Cramer, K., Neel, J., Bergeron, J., Barile, G.R., Smith, R.T., AMD Genetics Clinical Study Group, Hageman, G.S., Dean, M., Allikmets, R., Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat. Genet. 38 (2006), 458–462.
28. Haines, J.L., Hauser, M.A., Schmidt, S., Scott, W.K., Olson, L.M., Gallins, P., Spencer, K.L., Kwan, S.Y., Noureddine, M., Gilbert, J.R., Schnetz-Boutaud, N., Agarwal, A., Postel, E.A., Pericak-Vance, M.A., Complement factor H variant increases the risk of age-related macular degeneration. Science 308 (2005), 419–421.
29. Halstensen, T.S., Brandtzaeg, P., Local complement activation in inflammatory bowel disease. Immunol. Res. 10 (1991), 485–492.
30. Hillmen, P., Young, N.S., Schubert, J., Brodsky, R.A., Socié, G., Muus, P., Röth, A., Szer, J., Elebute, M.O., Nakamura, R., Browne, P., Risitano, A.M., Hill, A., Schrezenmeier, H., Fu, C.L., Maciejewski, J., Rollins, S.A., Mojcik, C.F., Rother, R.P., Luzzatto, L., The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 355 (2006), 1233–1243.
31. Hinz, C.F. Jr., Jordan, W.S. Jr., Pillemer, L., The properdin system and immunity. IV. The hemolysis of erythrocytes from patients with paroxysmal nocturnal hemoglobinuria. J. Clin. Invest., 35, 1956, 453.
32. Holers, V.M., Complement and its receptors: new insights into human disease. Annu. Rev. Immunol. 32 (2014), 433–459.
33. Hong, S., Beja-Glasser, V.F., Nfonoyin, B.M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K.M., Shi, Q., Rosenthal, A., Barres, B.A., Lemere, C.A., Selkoe, D.J., Stevens, B., Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352 (2016), 712–716.
34. Horváth, Z., Csuka, D., Vargova, K., Kovács, A., Molnár, A.Á., Gulácsi-Bárdos, P., Leé, S., Varga, L., Kiss, R.G., Préda, I., Füst, G., Elevated C1rC1sC1inh levels independently predict atherosclerotic coronary heart disease. Mol. Immunol. 54 (2013), 8–13.
35. Kavanagh, D., Goodship, T.H., Update on evaluating complement in hemolytic uremic syndrome. Curr. Opin. Nephrol. Hypertens. 16 (2007), 565–571.
36. Kawamata, T., Akiyama, H., Yamada, T., McGeer, P.L., Immunological reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. 140 (1992), 691–707.
37. Kawana, S., Geoghegan, W.D., Jordon, R.E., Nishiyama, S., Deposition of the membrane attack complex of complement in pemphigus vulgaris and pemphigus foliaceus skin. J. Inves. Dermatol. 92 (1989), 588–592.
38. Kelly, R.J., Hill, A., Arnold, L.M., Brooksbank, G.L., Richards, S.J., Cullen, M., Mitchell, L.D., Cohen, D.R., Gregory, W.M., Hillmen, P., Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 117 (2011), 6786–6792.
39. Kuroda, H., Fujihara, K., Takano, R., Takai, Y., Takahashi, T., Misu, T., Nakashima, I., Sato, S., Itoyama, Y., Aoki, M., Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. J. Neuroimmunol 254 (2013), 178–182.
40. Lee, M., Guo, J.-P., McGeer, E.G., McGeer, P.L., Aurin tricarboxylic acid self-protects by inhibiting aberrant complement activation at the C3 convertase and C9 binding stages. Neurobiol. Aging 34 (2013), 1451–1461.
41. Lee, M., Guo, J.-P., Schwab, C., McGeer, E.G., McGeer, P.L., Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic acid synthetic complex. Neurobiol. Aging 33 (2012), 2237–2246.
42. Lemaire, M., Fremmeaux-Bacchi, V., Schaefer, E., Choi, M., Tang, W.H., Le Quintrec, M., Fakhouri, F., Taque, S., Nobili, F., Martinez, F., Ji, W., Overton, J.D., Mane, S.M., Nürnberg, G., Altmüller, J., Thiele, H., Morin, D., Deschenes, G., Baudouin, V., Llanas, B., Collard, L., Majid, M.A., Simkova, E., Nürnberg, P., Rioux-Leclerc, N., Moeckel, G.W., Gubler, M.C., Hwa, J., Loirat, C., Lifton, R.P., Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat. Genet. 45 (2013), 531–536.
43. Lu, Y., Hu, X.B., C5a stimulates the proliferation of breast cancer cells via the Akt-dependent RGC-32 gene activation. Oncol. Rep. 32 (2014), 2813–2817.
44. Luo, J., Li, S., Qin, X., Song, L., Peng, Q., Chen, S., Xie, Y., Xie, L., Li, T., He, Y., Deng, Y., Wang, J., Zeng, Z., Meta-analysis of the association between CR 1 polymorphisms and risk of late-onset Alzheimer's disease. Neurosci. Lett. 578 (2014), 165–170.
45. Luzzatto, L., Paroxysmal nocturnal hemoglobinuria: an acquired X-linked genetic disease with somatic-cell mosaicism. Curr. Opin. Genet. Dev. 16 (2006), 317–322.
46. Mahmoudi, R., Kisserli, A., Novella, J.L., Alzheimer's disease is associated with low density of the long CR 1 isoform. Neurobiol. Aging 36 (2015), 1766.e5–1766.e12.
47. Mantovani, S., Gordon, R., Macmaw, J.K., Pfluger, C.M., Henderson, R.D., Noakes, P.G., McCombe, P.A., Woodruff, T.M., Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood. J. Neuroimmunol. 276 (2014), 213–218.
48. McConnell, J., Klein, G., Lint, T.F., Lachmann, P.J., Activation of the alternative complement pathway by human B-cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells. Eur. J. Immunol. 8 (1978), 453–458.
49. McGeer, P.L., Akiyama, H., Itagaki, S., McGeer, E.G., Immune system response in Alzheimer's disease. Can. J. Neurol. Sci. 16 (1989), 516–527.
50. McGeer, P.L., Akiyama, H., Itagaki, S., McGeer, E.G., Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci. Lett. 107 (1989), 341–346.
51. McGeer, P.L., McGeer, E.G., Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat. Disord. 10:Suppl 1 (2004), S3–S7.
52. McGeer, P.L., McGeer, E.G., The amyloid cascade-inflammatory hypothesis of Alzheimer disease. Acta Neuropathol. 126 (2013), 479–497.
53. McGeer, P.L., Rogers, J., McGeer, E.G., Sibley, J., Does anti-inflammatory treatment protect against Alzheimer disease?. Lancet, 335, 1990, 1037.
54. McGeer, P.L., Schulzer, M., McGeer, E.G., Arthritis and antiinflammatory agents as negative risk factors for Alzheimer disease: a review of seventeen epidemiological studies. Neurology 47 (1996), 425–432.
55. Michailidou, I., Willems, J.G., Kooi, E.J., van Eden, C., Gold, S.M., Geurts, J.J., Baas, F., Huitinga, I., Ramaglia, V., Complement C1q-C3-associated synaptic changes in multiple sclerosis hippocampus. Ann. Neurol. 77 (2015), 1007–1026.
56. Morgan, B.P., Campbell, A.K., Compston, D.A., Terminal component of complement (C9) in cerebrospinal fluid of patients with multiple sclerosis. Lancet 2 (1984), 251–254.
57. Morgan, B.P., Daniels, R.H., Williams, B.D., Measurement of terminal complement complexes in rheumatoid arthritis. Clin. Exp. Immunol. 73 (1988), 473–478.
58. Moyo, V.M., Mukhina, G.L., Garrett, E.S., Brodsky, R.A., Natural history of paroxysmal nocturnal hemoglobinuria using modern diagnostic assays Brit. J. Haematol. 166 (2004), 133–138.
59. Nakagawa, K., Sakiyama, H., Tsuchida, T., Yamaguchi, K., Toyoguchi, T., Masuda, R., Moriya, H., Complement C1s activation in degenerating articular cartilage of rheumatoid arthritis patient: immunohistochemical studies with an active form specific antibody. Ann. Rheum. Dis. 58 (1999), 175–181.
60. Niculescu, F., Rus, H.G., Retegan, M., Vlaicu, R., Persistent complement activation on tumor cells in breast cancer. Am J Pathol. 140 (1992), 1039–1043.
61. Niculescu, F., Rus, H.G., Vlaicu, R., Activation of the human terminal complement pathway in atherosclerosis. Clin. Immunol. 45 (1987), 147–155.
62. Nitta, H., Murakami, Y., Wada, Y., Baba, H., Imamura, T., Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness. Oncol. Rep. 32 (2014), 1715–1719.
63. Nitta, H., Wada, Y., Kawano, Y., Murakami, Y., Irie, A., Taniguchi, K., Kikuchi, K., Yamada, G., Suzuki, K., Honda, J., Wilson-Morifuji, M., Araki, N., Eto, M., Baba, H., Imamura, T., Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88). Clin. Cancer Res. 19 (2013), 2004–2013.
64. Nytrova, P., Pollukova, E., Kemlink, D., Woodhall, M., Horakova, D., Waters, P., Havrdova, E., Zivorova, D., Vincent, A., Trendelenburg, M., Complement activation in patients with neuromyelitis optica. J. Neuroimmunol 274 (2014), 185–191.
65. Okroj, M., Heinegard, D., Holmdahl, B., Blom, A.M., Rheumatoid arthritis and the complement system. Ann. Med. 1 (2007), 1–14.
66. Oksjoki, R., Laine, P., Helske, S., Vehmaan-Kreula, P., Mäyränpää, M.I., Gasque, P., Kovanen, P.T., Pentikäinen, M.O., Receptors for the anaphylatoxins C3a and C5a are expressed in human atherosclerotic coronary plaques. Atherosclerosis 195 (2007), 90–99.
67. Olmez, U., Garred, P., Mollnes, T.E., Harboe, M., Berntzen, H.B., Munthe, E., C3 activation products, C3 containing immune complexes, the terminal complement complex and native C9 in patients with rheumatoid arthritis. Scand. J. Rheumatol. 20 (1991), 183–189.
68. Pagoldh, M., Lange, S., Jennische, E., Almer, S., Bostrom, E.A., Eriksson, A., Faecal analysis and plasma complement factor C3 levels at admission for an acute attack of ulcerative colitis are predictive for the need for colectomy. Eur. J. Gastroenterol. Hepatol. 26 (2014), 295–300.
69. Patel, S.N., Berghout, J., Lovegrove, F.E., Ayi, K., Conroy, A., Serghides, L., Min-oo, G., Gowda, D.C., Sarma, J.V., Rittirsch, D., Ward, P.A., Liles, W.C., Gros, P., Kain, K.C., C5 deficiency and C5a or C5aR blockade protects against cerebral malaria. J. Exp. Med. 205 (2008), 1133–1143.
70. Perrin, L.H., Nydegger, U.E., Zubler, R.H., Lambert, P.H., Miescher, P.A., Correlation between levels of breakdown products of C3, C4 and properdin factor B in synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum. 20 (1977), 647–652.
71. Pio, R., Ajona, D., Lambris, J.D., Complement inhibition in cancer therapy. Semin. Immunol. 25 (2013), 54–64.
72. Pittock, S.J., Lennon, V.A., McKeon, A., Mandrekar, J., Weinshenker, B.G., Lucchinetti, C.F., O'Toole, O., Wingerchuk, D.M., Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 12 (2013), 554–562.
73. Potter, B.J., Hodgson, H.J., Mee, A.S., Jewell, D.P., C1q in ulcerative colitis and Crohn's disease. Gut 20 (1979), 1012–1019.
74. Radillo, O., Nocera, A., Leprini, A., Barocci, S., Mollnes, T.E., Pocecco, M., Pausa, M., Valente, U., Betterle, C., Tedesco, F., Complement-fixing islet cell antibodies in type-1 diabetes can trigger the assembly of the terminal complement complex on human islet cells and are potentially cytotoxic. Clin. Immunol. Immunopathol 79 (1996), 217–223.
75. Risitano, A.M., Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and anticomplement strategies. Adv. Exp. Med. 735 (2013), 155–172.
76. Risitano, A.M., Notaro, R., Pascariello, C., Sica, M., del Vecchio, L., Horvath, C.J., Fridkis-Hareli, M., Selleri, C., Lindorfer, M.A., Taylor, R.P., Luzzatto, L., Holers, V.M., The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment opsonization. Blood 119 (2012), 6307–6316.
77. Robson, K.J.H., Hall, J.R.S., Jennings, M.W., Harris, T.J.R., Marsh, K., Newbold, C.I., Tate, V.E., Weatherall, D.J., A highly conserved amino-acid sequence in thrombospondin, properdin and in proteins from sporozoites and blood stages of a human malaria parasite. Nature 335 (1988), 79–82.
78. Rogers, J., Cooper, N.R., Webster, S., Schultz, J., McGeer, P.L., Styren, S.D., Civin, W.H., Brachova, L., Bradt, B., Ward, P., Complement activation by b-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 89 (1992), 10016–10020.
79. Rosenberg, E.W., Noah, P.W., Wyatt, R.J., Jones, R.M., Kolb, W.P., Complement activation in psoriasis. Clin. Exp. Dermatol. 15 (1990), 16–20.
80. Rowe, P., Wasserfall, C., Croker, B., Campbell-Thompson, M., Pugliese, A., Atkinson, M., Schatz, D., Increased complement activation in human type 1 diabetes pancreatica. Diabetes Care 36 (2013), 3815–3817.
81. Ruddy, S., Fearon, D.T., Austen, K.F., Depressed synovial fluid levels of properdin and properdin factor B in patients with rheumatoid arthritis. Arthritis Rheum. 18 (1975), 289–295.
82. Rus, V., Malide, D., Boloşiu, H.D., Parasca, I., Duţu, A.L., Levels of SC5b-9 complement complex in plasma and synovial fluid of patients with rheumatoid arthritis. Med. Intern. 28 (1990), 305–310.
83. Rutkowski, M.J., Sughrue, M.E., Kane, A.J., Mills, S.A., Parsa, A.T., Cancer and the complement cascade. Mol. Cancer Res. 11 (2010), 1453–1465.
84. Sanders, M.E., Koski, C.L., Robbins, D., Shin, M.L., Frank, M.M., Joiner, K.A., Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis. J. Immunol. 136 (1986), 4456–4459.
85. Schmidt, C., Wolff, M., von Ahsen, N., Lange, K., Friede, T., Zerr, I., CR1 is potentially associated with rate of decline in sporadic Alzheimer's disease. J. Clin. Neurosci. 21 (2014), 1705–1708.
86. Schwab, C., McGeer, P.L., Complement activated C4d immunoreactive oligodendrocytes delineate early plaques in multiple sclerosis. Exp. Neurol. 174 (2002), 81–88.
87. Seah, P.P., Fry, L., Mazageri, M.R., Mowbray, J.F., Hoffbrand, A.V., Holborrow, E.J., Alternate-pathway complement fixation by IgA in the skin in dermatitis herpetiformis. Lancet 7822 (1973), 175–177.
88. Sekar, A., Bialis, A.R., deRivera, H., Davis, A., Hammond, T.R., Kamitaki, N., Tooley, K., Presumey, J., Baum, M., Van Doren, V., Genovese, G., Rose, S.A., Handsaker, R.E., Schizophrenia Working Group of the Psychiatric Genomics Consortium, Daly, M.J., Carroll, M.C., Stevens, B., McCarroll, S.A., Schizophrenia risk from complex variation of complement component 4. Nature 530 (2016), 177–183.
89. Silver, K.L., Higgins, S.J., McDonald, C.R., Kain, K.C., Complement driven innate immune response to malaria: fuelling severe malarial diseases. Cell Microbiol. 12 (2010), 1036–1045.
90. Speidl, W.S., Exner, M., Amighi, J., Kastl, S.P., Zorn, G., Maurer, G., Wagner, O., Huber, K., Minar, E., Wojta, J., Schillinger, M., Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur. Heart J. 26 (2005), 2294–2299.
91. Sta, M., Sylva-Steenland, R.M., Casula, M., deJong, L.M., Troost, D., Aronica, E., Baas, F., Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation Neurobiol. Aging 42 (2011), 211–220.
92. Stahel, P.F., Morganti-Kossmann, M.C., Perez, D., Redaelli, C., Gloor, B., Trentz, O., Kossmann, T., Intrathecal levels of complement-derived soluble membrane attack complex (sC5b-9) correlate with blood-brain barrier dysfunction in patients with traumatic brain injury. J. Neurotrauma 18 (2001), 773–781.
93. Sundsmo, J.S., Papin, R.A., Wood, L., Hirani, S., Waldeck, N., Buckingham, B., Kershnar, A., Ascher, M., Charles, M.A., Complement activation in type 1 human diabetes. Clin. Immunol. Immunopathol 35 (1985), 211–225.
94. Takeda, J., Miyata, T., Kawagoe, K., Iida, Y., Endo, Y., Fujita, T., Takahashi, M., Kitani, T., Kinoshita, T., Deficiency of the GPI anchor caused by a somatic mutation in the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 73 (1993), 703–711.
95. Takematsu, H., Tagami, H., Generation of terminal complement complexes in psoriatic lesioned skin. Dermatology 185 (1992), 246–250.
96. Terai, K., McGeer, E.G., McGeer, P.L., Neurons express proteins of the classical complement pathway in Alzheimer disease. Brain Res. 769 (1997), 385–390.
97. Thompson, I.A., Liu, B., Sen, H.N., Jiao, X., Katamay, R., Li, Z., Hu, M., Hejtmancik, F., Nussenblatt, R.B., Association of complement factor H tyrosine 402 histidine genotype with posterior involvement in sarcoid-related uveitis. Am. J. Ophthalmol. 155 (2013), 1068–1074.
98. Torzewski, J., Torzewski, M., Bowyer, D.E., Fröhlich, M., Koenig, W., Waltenberger, J., Fitzsimmons, C., Hombach, V., C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler. Thromb. Vasc. Biol. 18 (1998), 1386–1392.
99. Triolo, G., Accardo-Palumbo, A., Sallì, L., Ciccia, F., Ferrante, A., Tedesco, L., Sallì, S., Giardina, E., Pappalardo, A., Licata, G., Impaired expression of erythrocyte glycol-phosphotidylinosotol-anchored membrane CD59 in patients with psoriatic arthritis. Relation to terminal complement pathway activation. Clin. Exp. Rheumatol. 21 (2003), 225–228.
100. Uzawa, A., Mori, M., Kuwabara, S., Neuromyelitis optica: concept. Immunology and treatment. J. Clin. Neurosci. 21 (2014), 12–21.
101. Van de Goot, E., Krijnen, P.A., Begieneman, M.P., Ulrich, M.M., Middelkoop, E., Niessen, H.W., Acute inflammation is persistent in burn wounds: a pivotal role for complement and C-reactive protein. J. Burn Care Res. 30 (2009), 274–280.
102. Vergani, S., Di Mauro, E., Davies, E.T., Spinelli, D., Mieli-Vergani, G., Vergani, D., Complement activation in uveitis. Br. J. Ophthalmol. 70 (1986), 60–63.
103. Veszeli, N., Fust, G., Csuka, D., Trauninger, A., Bors, L., Rozsa, C., Nagy, Z., Jobbágy, Z., Eizler, K., Prohászka, Z., Varga, L., Illes, Z., A systematic analysis of the complement pathways in patients with neuromyelitis optica indicates alteration but no activation during remission. Mol. Immunol. 57 (2014), 200–209.
104. Villemagne, V.L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K.A., Salvado, O., Szoeke, C., Macaulay, S.L., Martins, R., Maruff, P., Ames, D., Rowe, C.C., Masters, C.L., Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 13 (2013), 70044–70049.
105. Vlaicu, R., Niculescu, F., Rus, H.G., Cristea, A., Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis 57 (1985), 163–177.
106. Walker, D.G., McGeer, P.L., Complement gene expression in human brains: comparison between normal and Alzheimer disease cases. Mol. Brain Res. 14 (1992), 109–116.
107. Wan, K.C., Lewis, W.H., Leung, P.C., Chien, P., Hung, L.K., A longitudinal study of C3, C3d, and factor Ba in burn patients in Hong Kong Chinese. Burns 24 (1998), 241–244.
108. Wang, H., Wang, K., Wang, C., Qiu, W., Lu, Z., Hu, X., Increased soluble C5b-9 in CSF of neuromyelitis optica. Scand. J. Immunol. 79 (2014), 127–130.
109. Wang, Y., Huang, X.F., Yang, M.M., Cai, W.J., Zheng, M.Q., Mao, G., Pang, C.P., Jin, Z.B., CFl-rs 7356506 is a genetic protective factor for acute anterior uveitis in Chinese patients. B. J. Ophthalmol. 98 (2014), 1592–1596.
110. Wingerchuk, D.M., Neuromyelitis optica: new findings on pathogenesis. Int. Rev. Neurobiol. 79 (2007), 665–688.
111. Wouters, D., Voskuyl, A.E., Molenaar, E.T., Dijkmans, B.A., Hack, C.E., Evaluation of classical complement pathway activation in rheumatoid arthritis: measurement of C1q-C4 complexes as novel activation products. Arthritis Rheum. 54 (2006), 1143–1150.
112. Yamada, T., McGeer, P.L., McGeer, E.G., Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol. 84 (1992), 100–104.
113. Yasojima, K., Schwab, C., McGeer, E.G., McGeer, P.L., Upregulated production and activation of the complement system in Alzheimer disease brain. Am. J. Pathol. 154 (1999), 927–936.
114. Yasojima, K., Schwab, C., McGeer, E.G., McGeer, P.L., Complement components, but not the complement regulators C1 inhibitor and CD59, are upregulated in atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 21 (2001), 1214–1219.
115. Yates, J.R., Sepp, T., Matharu, B.K., Khan, J.C., Thurlby, D.A., Shahid, H., Clayton, D.G., Hayward, C., Morgan, J., Wright, A.F., Armbrecht, A.M., Dhillon, B., Deary, I.J., Redmond, E., Bird, A.C., Moore, A.T., Genetic Factors in AMD Study Group. Complement C3 variant and the risk of age-related macular degeneration. N. Engl. J. Med. 357 (2007), 553–561.
116. Zimmerman-Nielsen, E., Gronbaek, H., Dahlerup, J.F., Baatrup, G., Thorlacius-Ussing, O., Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn's disease and ulcerative colitis. BMC Gastroenterol., 22, 2005, 531.